Modulating PKCα Activity to Target Wnt/β-Catenin Signaling in Colon Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Inactivating mutations in Adenomatosis Polyposis Coli (APC) are common in colorectal cancer (CRC), leading to uncontrolled Wnt/β-catenin signaling and tumor growth.
• The Wnt/β-catenin pathway is crucial for intestinal development, but its dysregulation drives CRC pathogenesis.
• Targeting downstream effectors of APC, such as β-catenin stability and co-transcriptional activity, presents a therapeutic strategy for CRC.

Purpose of the Study:

• To investigate the therapeutic potential of enhancing Protein Kinase C-alpha (PKCα) function in colorectal cancer (CRC).
• To determine if increased PKCα activity is detrimental to normal intestinal cells or beneficial for CRC treatment.

Main Methods:

• Utilized in vitro (DLD-1 cells) and in vivo (C57BL/6J mice) models with induced PKCα function.
• Analyzed PKCα mutation frequency in CRC patient samples.
• Assessed the effect of di-terpene ester-induced PKCα activity on CRC cell viability and normal intestinal epithelium.

Main Results:

• PKCα is rarely mutated in CRC, indicating its function can be modulated therapeutically.
• Enhanced PKCα activity did not harm normal intestinal epithelial cells.
• PKCα activation by di-terpene esters effectively induced colorectal cancer cell death.

Conclusions:

• PKCα plays a role in regulating β-catenin, a key driver of CRC.
• Enhancing PKCα function represents a viable and safe therapeutic strategy for colorectal cancer.
• PKCα is identified as a relevant drug target for CRC treatment.